Targeted therapy continues to redefine treatment strategies for metastatic non–small cell lung cancer (NSCLC), particularly for tumors driven by BRAF V600E, MET exon 14–skipping alterations, and KRAS G12C mutations. During a presentation at the 20th Annual New York Lung Cancers...
Short CommunicationVolume 209108749November 2025Download Full Issue Download started OkKRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effectsMeng LiuMeng Liu 0000-0003-3781-6962AffiliationsDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USASearch for...
"[In the near future], we probably will see KRAS G12C inhibitors combined with either other bispecific antibodies or antibody-drug conjugates to amplify their benefit." Xiuning Le, MD, PhD, an associate professor in the Department of Thoracic/Head and Neck Medical Oncology...
Moffitt Cancer Center Studies Highlight Strategies to Overcome Drug Resistance in KRAS G12C-Mutant NSCLC Researchers at the Moffitt Cancer Center have published two studies in *Cancer Research* detailing new strategies to address drug resistance in KRAS G12C-mutant non-small cell lung...
Two preclinical studies from Moffitt Cancer Center show that combining KRAS G12C inhibitors with CDK12/13 inhibitors produces a synergistic effect, delaying resistance by targeting both RAS-driven growth and repair/mitotic dependencies. Resistance to KRAS G12C inhibitors arises from reactivated RAS signaling...
The therapeutic approach to advanced non-small cell lung cancer (NSCLC) relies on dichotomizing non-oncogene-addicted and oncogene-addicted diseases according to predictive biomarkers [1–3]. Immune checkpoint inhibitors (ICI) represent the cornerstone of treatment for non-oncogene-addicted NSCLC Research ArticleVolume 199108058January 2025Open accessDownload Full...
Elironrasib, a novel RAS G12C–selective tri-complex inhibitor, demonstrated initial clinical activity and a differentiated safety profile in heavily pretreated patients with non–small cell lung cancer (NSCLC) and KRAS G12C mutations, according to findings from a phase I trial presented at...
Lung Cancer is the second most common cause of cancer and remains the leading cause of cancer death.[1,2] Non-small cell lung cancer (NSCLC) accounts for 81 % of lung cancers with most patients presenting in advanced stages.[3,4,5] NSCLC, in particular lung...
Lung Cancer is the second most common cause of cancer and remains the leading cause of cancer death.[1,2] Non-small cell lung cancer (NSCLC) accounts for 81 % of lung cancers with most patients presenting in advanced stages.[3,4,5] NSCLC, in particular lung...
